Skip to main content

Advertisement

SpringerLink
Log in

Pharmacogenomics of multigenic diseases: Sex-specific differences in disease and treatment outcome

  • Published:
AAPS PharmSci Aims and scope Submit manuscript

Abstract

Numerous genetic variations have been shown to affect disease susceptibility and drug response. Pharmacogenomics aims at improving therapy on the basis of genetic information for each individual patient. Furthermore, sex chromosomes broadly determine biological differences between males and females. Consequently, substantial sex differences exist in phenotypic manifestation of disease and treatment response. This review discusses the role of sex in coronary artery disease, schizophrenia, and depression—complex multigenic disorders with considerable sex differences in frequency and presentation. Moreover, genetic factors underlying disease and drug response appear to differ between male and female patients. This appears to result at least in part from different physiological effects exerted by sex hormones such that polymorphisms in susceptibility genes may have physiological relevance only in males or females. However, few examples have been discovered to play a role in complex multigenic diseases, and the mechanistic basis of genetic variants as sex-dependent susceptibility factors has yet to be explored. Therefore, pharmacogenomic studies must consider sex differences in an effort to optimize individual drug therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Ono S. Sex Chromosomes and Sex-linked Genes. Berlin, Germany, Springer-Verlag; 1967.

    Book  Google Scholar 

  2. Skaletsky H, Kuroda-Kawaguchi T, Minx P, et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature. 2003;423(6942):825–837.

    Article  CAS  PubMed  Google Scholar 

  3. Chinnery P, Turnbull D. Mitochondrial DNA mutations in the pathogenesis of human disease. Mol Med Today. 2000;6:425–432.

    Article  CAS  PubMed  Google Scholar 

  4. Barrett A, Smith E, Picker M. Sex-related differences in mechanical nociception and antinociception produced by mu- and kappa-opioid receptor agonists in rats. Eur J Pharmacol. 2002;452:163–173.

    Article  CAS  PubMed  Google Scholar 

  5. Mogil J, Wilson S, Chesler E, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 2003;100:4867–4872.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Anthony M., Berg M. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharma-cogenetics: Part II. J Womens Health Gend Based Med. 2002;11:617–629.

    Article  PubMed  Google Scholar 

  7. Schwartz J. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107–121.

    Article  CAS  PubMed  Google Scholar 

  8. Cambien F, Poirier O, Nicand V, et al. Sequence diversity in 36 candidate genes for cardiovascular disorders. Am J Hum Genet. 1999;65:183–191.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Lusis A. Atherosclerosis. Nature. 2000;407:233–241.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Massart F., Reginster J, Brandi M. Genetics of menopause diseases. Maturitas. 2001;40:103–116.

    Article  CAS  PubMed  Google Scholar 

  11. Bodnar J, Chatterjee A, Castellani L, et al. Positional cloning of the combined hyperlipidemia gene Hyplip 1. Nat Genet. 2002;30(1):110–116.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Zwarts K, Clee S, Zwinderman A, et al. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet. 2002;61:115–125.

    Article  CAS  PubMed  Google Scholar 

  13. Cardiovascular candidate gene polymorphisms. GeneCanvas Web site. Available at: http://genecanvas.idf.inserm.fr/.Accessed August 2002 through August 2003.

  14. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. New Engl J Med. 2002;347:1916–1923.

    Article  CAS  PubMed  Google Scholar 

  15. Wilson M, Grant P, Kain K, Warner D, Wild C. Association between the risk of coronary artery disease in South Asians and a deletion polymorphism in glutathione S-transferase M1. Biomarkers. 2003;8(1):43–50.

    Article  CAS  PubMed  Google Scholar 

  16. Olshan A, Li R, Pankow J, et al. Risk of atherosclerosis: interaction of smoking and glutathione S-transferase genes. Epidemiology. 2003;14(3):321–327.

    PubMed  Google Scholar 

  17. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: encyclopedia for genes, proteins and diseases. GeneCards, an academic Web site of Weizmann Institute of Science, Bioinformatics Unit and Genome Center: Available at: http://bioinformatics.weizmann.ac.il/cards. Accessed August 2003.

  18. Povey S, Wain H, Bruford E, et al. Approved Symbols. HUGO Gene Nomenclature Committee Web site. Available at: http://www.gene.ucl.ac.uk/nomenclature/.Accessed August 2003.

  19. Kyker K, Limacher M. Gender differences in the presentation and symptoms of coronary artery disease. Curr Womens Health Rep. 2002;2:115–119.

    PubMed  Google Scholar 

  20. Lee W, Cheung A, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men. Diabetes Care. 2000;23:962–968.

    Article  CAS  PubMed  Google Scholar 

  21. Kingwell B, Medley T, Waddell T, Cole T, Dart A, Jennings G. Large artery stiffness: structural and genetic aspects. Clin Exp Pharmacol Physiol. 2001;28:1040–1043.

    Article  CAS  PubMed  Google Scholar 

  22. De Oliveira e Silva E, Kong M, Han Z, et al. Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normolipidemic females. Lipid Res. 1999;40:1211–1221.

    Google Scholar 

  23. Ordovas J, Cupples L, Corella D, Otvos J, Osgood D, Martinez A, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. Arterioscler. Thromb Vasc Biol. 2000;20:1323–1329.

    Article  CAS  PubMed  Google Scholar 

  24. Kuivenhoven J, Jukema J, Zwinderman A, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med. 1998;338:86–93.

    Article  CAS  PubMed  Google Scholar 

  25. Herrington D, Howard T, Hawkins G, Reboussin D, Xu J, Zheng S, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002;346:967–974.

    Article  CAS  PubMed  Google Scholar 

  26. Anttila S, Kampman O, Illi A, et al. NOTCH4 gene promoter polymorphism is associated with the age of onset in schizophrenia. Psychiatr Genet. 2003;13:61–64.

    PubMed  Google Scholar 

  27. Bjelland I, Tell G, Vollset S, Refsum H, Ueland P. Folate, vitamin B12, homocysteine, and the MTHFR 677C»T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry. 2003;60:618–626.

    Article  CAS  PubMed  Google Scholar 

  28. Blakely R. Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci. 2001;21:8319–8323.

    CAS  PubMed  Google Scholar 

  29. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A. 2002;99(21):13675–13680.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Emilien G, Maloteaux J, Geurts M, Hoogenberg K, Cragg S. Dopamine receptors—physiological understanding to therapeutic intervention potential. Pharmacol Ther. 1999;84:133–156.

    Article  CAS  PubMed  Google Scholar 

  31. Harrison P, Owen M. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 2003;361:417–419.

    Article  CAS  PubMed  Google Scholar 

  32. Huang Y, Oquendo M, Friedman J, et al. Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology. 2002;28:163–169.

    Article  Google Scholar 

  33. Huber J, Schneeberger C, Tempfer C. Genetic modeling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas. 2002;42:1–12.

    Article  CAS  PubMed  Google Scholar 

  34. Ilani T, Ben-Shacher D, Strous R, et al. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci USA. 2001;98(2):625–628.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Itokawa M, Arai M, Kato S, et al. Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett. 2003;347:202–204.

    Article  CAS  PubMed  Google Scholar 

  36. Jacquet H, Raux G, Thibaut F, et al. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum Mol Genet. 2002;11(19):2243–2249.

    Article  CAS  PubMed  Google Scholar 

  37. Joffe H, Cohen L. Estrogen, serotonin and mood disturbance: where is the therapeutic bridge? Biol Psychiatry. 1998;44:798–811.

    Article  CAS  PubMed  Google Scholar 

  38. Jones I, Middle F, McCandless F, Coyle N, Robertson E, Brockington I. Molecular genetic studies of bipolar disorder and puerperal psychosis at two polymorphisms in the estrogen receptor alpha gene (ESR 1). Am J Med Genet. 2000;96:850–853.

    Article  CAS  PubMed  Google Scholar 

  39. Millar JK, Wilson-Annan J, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2002;9:1415–1423.

    Article  Google Scholar 

  40. Mirnics K, Middleton F, Stanwood G, Lewis D, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry. 2001;6(3):293–301.

    Article  CAS  PubMed  Google Scholar 

  41. Ouyang W, Wang Y, Hong C, Tsai S. Estrogen receptor alpha gene polymorphisms in schizophrenia: frequency, age at onset, symptomology and prognosis. Psychiatr Genet. 2001;11:95–98.

    Article  CAS  PubMed  Google Scholar 

  42. Rybakowski J, Borkowska A, Czerski P, Dmitrzak-Weglarz M, Hauser J. The study of cytosolic phospholipase A2 gene polymorphism in schizophrenia using eye movement disturbances as an endophenotypic marker. Neuropsychobiology. 2003;47:115–119.

    Article  PubMed  Google Scholar 

  43. Toulouse A, Rochefort D, Roussel J, Joober R, Roulean G. Molecular cloning and characterization of human RAI1, a gene associated with schizophrenia. Genomics. 2003;82:162–171.

    Article  CAS  PubMed  Google Scholar 

  44. Veenstra-VanderWeele J, Anderson G, Cook E. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol. 2000;410:165–181.

    Article  CAS  PubMed  Google Scholar 

  45. Virgos C, Martorell L, Valero J, et al. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res. 2001;49:65–71.

    Article  CAS  PubMed  Google Scholar 

  46. Xie T, Ho S, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol. 1999;56:31–38.

    CAS  PubMed  Google Scholar 

  47. Yu Y, Chen T, Wang Y, Liou Y, Hong C, Tsai S. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology. 2003;47:137–140.

    Article  CAS  PubMed  Google Scholar 

  48. Zill P, Baghai T, Engel R, et al. Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response. Am J Med Genet. 2003;120B:85–89.

    Article  PubMed  Google Scholar 

  49. Bray N, Buckland P, Williams N, et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet. 2003;73:152–161.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Caspi A, Sugden K, Moffitt T, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386–389.

    Article  CAS  PubMed  Google Scholar 

  51. Wonodi I, Stine O, Mitchell B, Buchanan R, Thaker G. Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet. 2003;120B:47–50.

    Article  PubMed  Google Scholar 

  52. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4):877–892.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Angold A, Costello E, Erkanli A, Worthman C. Pubertal changes in hormonal levels and depression in girls. Psychol Med. 1999;29:1043–1053.

    Article  CAS  PubMed  Google Scholar 

  54. Quitkin F, Stewart J, McGrath P, et al. Are there differences between women's and men's antidepressant responses?. Am J Psychiatry. 2002;159:1848–1854.

    Article  PubMed  Google Scholar 

  55. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Neuropsychopharmacology. 2002;5:255–275.

    CAS  Google Scholar 

  56. Kim K, Lim S, Lee S, et al. Serotonin transporter gene and anti-depressant response. Neuroreport. 2000;11:215–219.

    Article  CAS  PubMed  Google Scholar 

  57. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the serotonin transporter and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508–511.

    Article  CAS  PubMed  Google Scholar 

  58. Ahokas A, Turtiainen S, Aito M. Sublingual oestrogen treatment of postnatal depression. Lancet. 1998;351:109.

    Article  CAS  PubMed  Google Scholar 

  59. Ahokas A, Kaukoranta J, Aito M. Effect of oestradiol on postpartum depression. Psychopharmacology (Berl). 1999;146:108–110.

    Article  CAS  Google Scholar 

  60. Ahokas A, Aito M, Rimon R. Positive treatment effect of estradiol in postpartum psychosis: a pilot study. J Clin Psychiatry. 2000;61:166–169.

    Article  CAS  PubMed  Google Scholar 

  61. Sichel D, Cohen L, Robertson L, Ruttenberg A, Rosenbaum J. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry. 1995;38:814–818.

    Article  CAS  PubMed  Google Scholar 

  62. Schneider L, Small G, Hamilton S, Bystritsky A, Nemeroff C, Meyers B. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry. 1997;5:97–106.

    Article  CAS  PubMed  Google Scholar 

  63. Herrington D. Role of estrogen receptor-alpha in pharmacogenetics of estrogen action. Curr Opin Lipidol. 2003; 14(2):145–150.

    Article  CAS  PubMed  Google Scholar 

  64. Carlsson A, Waters N, Carlsson M. Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur Arch Psychiatry Clin Neurosci. 1999;249:S37-S43.

    Article  Google Scholar 

  65. Stevens J. Schizophrenia: reproductive hormones and the brain. Am J Psychiatry. 2002;159:713–719.

    Article  PubMed  Google Scholar 

  66. Grigoriadis S, Seeman M. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry. 2002;47:437–442.

    PubMed  Google Scholar 

  67. Preston N, Orr K, Date R, Nolan L, Castle D. Gender differences in premorbid adjustment of patients with first episode psychosis. Schizophr Res. 2002;55:285–290.

    Article  PubMed  Google Scholar 

  68. Cowell P, Kostianovsky D, Gur R, Turetsky B, Gur R. Sex differences in neuroanatomical and clinical correlations in schizophrenia. Am J Psychiatry. 1996;153(6):799–805.

    Article  CAS  PubMed  Google Scholar 

  69. Kuppers E, Ivanova T, Karolczak M, Beyer C. Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons. J. Neurocytol. 2000;29(5–6):375–385.

    Article  CAS  PubMed  Google Scholar 

  70. Beyer C, Ivanova T, Karolczak M, Kuppers E. Cell type-specificity of nonclassical estrogen signaling in the developing mid-brain. J Steroid Biochem Mol Biol. 2002;81(4–5):319–325.

    Article  CAS  PubMed  Google Scholar 

  71. Raap D, DonCarlos L, Garcia F, et al. Ovariectomy-induced increases in hypothalamic serotonin-1A receptor function in rats are prevented by estradiol. Neuroendocrinology. 2002;76(6):348–356.

    Article  CAS  PubMed  Google Scholar 

  72. Arranz M, Kerwin R. Neurotransmitter related genes and antipsychotoic response: pharmacogenetics meets psychiatric treatment. Ann Med. 2000;32:128–133.

    Article  CAS  PubMed  Google Scholar 

  73. Larsen T, Friis S, Haahr U, et al. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr Scand. 2001;103:323–324.

    Article  CAS  PubMed  Google Scholar 

  74. Ichikawa J, Meltzer H. Relationship between dopaminergic and seratonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 4):90–98.

    Article  PubMed  Google Scholar 

  75. Arranz M, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet. 2000;355:1615–1616.

    Article  CAS  PubMed  Google Scholar 

  76. Zhao H, Pfeiffer R, Gail M. Haplotype analysis in population genetics and association studies. Pharmacogenomics. 2003;4:171–178.

    Article  PubMed  Google Scholar 

  77. Garner C, Slatkin M. On selecting markers for association studies: patterns of linkage disequilibrium between two and three diallelic loci. Genet Epidemiol. 2003;24(1):57–67.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Ohio State University, 333 W. 10th Avenue, 43210, Columbus, OH

    Julia Pinsonneault & Wolfgang Sadée

Authors
  1. Julia Pinsonneault
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Sadée
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Sadée.

Additional information

Published: November 5, 2003

An abbreviated version of this article, entitled “Pharmacogenomics: Sex Matters”, has been published in AAPS Newsmagazine, July 2003;6(7): 18–21, 44.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pinsonneault, J., Sadée, W. Pharmacogenomics of multigenic diseases: Sex-specific differences in disease and treatment outcome. AAPS PharmSci 5, 29 (2003). https://doi.org/10.1208/ps050429

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/ps050429

Keywords

Search

Navigation